Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Hematology|March 10, 2004
The Fifth Nagoya International Blood And Marrow Transplantation Symposium: unlimited possibilities of hematopoietic cell transplantation: lessons from the past and prospects for the futureHikaru Nakajima, Yoshiki Akatsuka
Bioorganic & Medicinal Chemistry|June 2, 2009
Synthesis of hybrid analogues of caffeine and eudistomin D and its affinity for adenosine receptorsHaruaki Ishiyama, Hikaru Nakajima, Hiroyasu Nakata, et al.
Cancer Science|February 26, 2010
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patientsToru Mukohara, Hikaru Nakajima, Hirofumi Mukai, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patientsHikaru Nakajima, Robert Zhao, Troy C Lund, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 30, 2004
[Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer]Masayuki Oki, Kiyoshi Ando, Hikaru Nakajima, et al.
Scientific Reports|August 25, 2017
Mapping of electromagnetic waves generated by free-running self-oscillating devicesShintaro Hisatake, Hikaru Nakajima, Hai Huy Nguyen Pham, et al.
Organic Letters|July 21, 2017
Atropisomeric Chiral Diiododienes (Z,Z)-2,3-Di(1-iodoalkylidene)tetralins: Synthesis, Enantiomeric Resolution, and Application in Asymmetric CatalysisMasamichi Ogasawara, Hirotaka Sasa, Hao Hu, et al.
Angewandte Chemie (International Ed. in English)|October 30, 2013
Atropisomeric chiral dienes in asymmetric catalysis: C(2) -symmetric (Z,Z)-2,3-bis[1-(diphenylphosphinyl)ethylidene]tetralin as a highly active Lewis base organocatalystMasamichi Ogasawara, Shunsuke Kotani, Hikaru Nakajima, et al.
Cancer Science|May 15, 2008
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumorsHironobu Minami, Kenji Kawada, Hiromichi Ebi, et al.
Pageof 1